Literature DB >> 19183077

Tenofovir-associated nephrotoxicity in two HIV-infected adolescent males.

Sarah M Wood1, Samir S Shah, Andrew P Steenhoff, Kevin E C Meyers, Bernard S Kaplan, Richard M Rutstein.   

Abstract

We report two cases of tenofovir (TDF)-associated nephrotoxicity in perinatally HIV-infected adolescents. The first case, a 16-year-old African American male with an absolute CD4+ cell count of 314 cells/mm(3), presented with an abrupt rise in serum creatinine leading to irreversible renal failure while on TDF-containing highly active antiretroviral therapy (HAART). While the patient had evidence of underlying kidney disease, the timing of his renal failure indicates that TDF played a central role. The second case, a 16-year-old African-American male with an absolute CD4+ cell count of 895 cells/mm3, presented with rickets and hypophosphatemia while receiving TDF-based HAART. To our knowledge, these cases represent the first reports of TDF-associated irreversible renal failure and rickets in pediatric patients. We believe these cases highlight important and potentially irreversible side effects of this agent and emphasize the need for further studies of the renal safety of TDF in pediatric patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19183077     DOI: 10.1089/apc.2008.0106

Source DB:  PubMed          Journal:  AIDS Patient Care STDS        ISSN: 1087-2914            Impact factor:   5.078


  5 in total

Review 1.  Update on tenofovir toxicity in the kidney.

Authors:  Andrew M Hall
Journal:  Pediatr Nephrol       Date:  2012-08-10       Impact factor: 3.714

Review 2.  Renal and Bone Adverse Effects of a Tenofovir-Based Regimen in the Treatment of HIV-Infected Children: A Systematic Review.

Authors:  Rose I Okonkwo; Anita E Weidmann; Emmanuel E Effa
Journal:  Drug Saf       Date:  2016-03       Impact factor: 5.606

3.  The Incidence and Clinical Characteristics of Acute Serum Creatinine Elevation more than 1.5 mg/dL among the Patients Treated with Tenofovir/Emtricitabine-containing HAART Regimens.

Authors:  Sun Jin; Myung Hi Kim; Jung Hwa Park; Hye Jin Jung; Hye Jin Lee; Shin-Woo Kim; Jong Myung Lee; Sujeong Kim; Hyun-Ha Chang
Journal:  Infect Chemother       Date:  2015-12-30

4.  Maternal and infant renal safety following tenofovir disoproxil fumarate exposure during pregnancy in a randomized control trial.

Authors:  Kristin Baltrusaitis; Bonus Makanani; Camlin Tierney; Mary Glenn Fowler; Dhayendre Moodley; Gerhard Theron; Lynette H Nyakudya; Musunga Tomu; Lee Fairlie; Kathleen George; Barbara Heckman; Kevin Knowles; Renee Browning; George K Siberry; Taha E Taha; Lynda Stranix-Chibanda
Journal:  BMC Infect Dis       Date:  2022-07-20       Impact factor: 3.667

Review 5.  A review of cardiovascular and renal function monitoring: a consideration of older adults with HIV.

Authors:  Clark D Kebodeaux; Alexandria Garavaglia Wilson; Daron L Smith; Scott Martin Vouri
Journal:  HIV AIDS (Auckl)       Date:  2013-09-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.